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Objective: Cyclooxygenase-2 (COX-2) is a major prostaglandin E2 (PGE2) synthetic enzyme and is involved
in the pathogenesis of chronic inﬂammation and pain in osteoarthritis (OA). The objective of this study
was to directly address whether microRNA (miR)-558 can control the interleukin (IL)-1b-mediated in-
duction of COX-2 and catabolic effects in human articular chondrocytes.
Materials and methods: Total RNA was extracted from the cartilage tissues of normal and OA donors or
cultured human articular chondrocytes. The expression of miR-558 was quantiﬁed by TaqMan assay. To
investigate the repressive effect of miR-558 on COX-2 expression, human chondrocytes and chondro-
genic SW1353 cells were transfected with mature miR-558 or an antisense inhibitor (anti-miR-558). The
expression of COX-2 protein was determined byWestern blot analysis and the involvement of miR-558 in
IL-1b-induced catabolic effects was examined by Western blot analysis and enzyme-linked immuno-
sorbent assay (ELISA). Direct interaction between miR-558 and the putative site in the 30-untranslated
region (UTR) of COX-2 messenger RNA (mRNA) was validated by luciferase reporter assay.
Results: Normal human articular cartilage expressed miR-558, and its expression was signiﬁcantly lower
in OA cartilage. Stimulation with IL-1b led to a signiﬁcant reduction in miR-558 expression in normal and
OA chondrocytes. IL-1b-induced activation of MAP kinase (MAPK) and nuclear factor-kB (NF-kB)
decreased miR-558 expression and induced COX-2 expression in chondrocytes. The overexpression of
miR-558 directly suppressed the luciferase activity of a reporter construct containing the 30-UTR of
human COX-2 mRNA and signiﬁcantly inhibited IL-1b-induced upregulation of COX-2, while treatment
with anti-miR-558 enhanced IL-1b-induced COX-2 expression and reporter activity in chondrocytes.
Interestingly, IL-1b-induced activation of NF-kB and expression of matrix metalloproteinase (MMP)-1
and MMP-13 was signiﬁcantly inhibited by miR-558 overexpression.
Conclusion: These ﬁndings demonstrated that cartilage homeostasis is inﬂuenced by miR-558, which
directly targets COX-2 and regulates IL-1b-stimulated catabolic effects in human chondrocytes.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a chronic degenerative joint disease
characterized by progressive destruction of articular cartilage, and
pain resulting in disability1e4. It is widely accepted that the
development of OA is associated with excessive production of in-
ﬂammatory cytokines such as interleukin (IL)-1b5. Published evi-
dence indicates that IL-1b has a pivotal role in cartilage matrixH.A. Kim, Division of Rheu-
University Sacred Heart Hos-
blic of Korea. Tel: 82-31-380-
Park), jjaymedi@gmail.com
.kr (H.A. Kim).
s Research Society International. Pdestruction via upregulation of the production of proteases, such as
matrix metalloproteinase (MMPs), and downregulation of the
synthesis of proteoglycan and collagen6e8. It can also induce
excessive cyclooxygenase-2 (COX-2) expression, leading to elevated
production of prostaglandin E2 (PGE2)9. Although very low levels of
PGE2 may have anabolic functions in cartilage, nano- tomicromolar
concentrations produced by OA tissues are predominantly cata-
bolic, leading to an inhibition of proteoglycan synthesis, increased
MMP-13 and increased type II collagen degradation10. Thus, PGE2,
which is found at high levels in synovial ﬂuid in OA patients and OA
animal models, is regarded as a possible therapeutic target in OA11.
Non-steroidal anti-inﬂammatory drugs (NSAIDs), the main func-
tion of which is to inhibit COX and to impair production of PGE2,
have long been used to treat pain and inﬂammation associated
with OA12.ublished by Elsevier Ltd. All rights reserved.
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taining 20e25 nucleotides that can regulate gene expression by
binding the 30-untranslated region (UTR) of their target messenger
RNA (mRNA), leading to translational repression or mRNA cleav-
age13. To date, many reports have demonstrated that miRNAs
function in diverse biological processes, including cell differentia-
tion, proliferation, and development14,15. Alterations in miRNA
expression are closely related to human diseases, such as heart
disease and arthritis16e18. Additionally, an important role of miRNA
in cartilage development was demonstrated by a report examining
cartilage-speciﬁc Dicer-null mice, which lack an essential compo-
nent for the biogenesis of miRNA. Dicer-null plates showed greatly
reduced chondrocyte proliferation and accelerated hypertrophic
differentiation, leading to severe skeletal growth defects and pre-
mature death19. Genetic modiﬁcation of miR-140 inﬂuenced the
development of OA in model animals, with miR-140 (/) mice
showing proteoglycan loss and ﬁbrillation of articular cartilage20.
In a previous report, miR-558 was reported to be signiﬁcantly
downregulated by IL-1b in human OA chondrocytes21. MiR-558 was
ﬁrst identiﬁed in human colorectal cells and subsequently found to
be upregulated in irradiated ﬁbroblasts and noted for targeting
genes involved in cell cycle checkpoints and apoptosis22,23. Using
the miRNA target prediction algorithms, we found that miR-558
has the potential to regulate COX-2 expression.
In this study, we found that miR-558 regulates COX-2 expres-
sion, suggesting its potential role in cartilage homeostasis. These
ﬁndings indicate that reduced miR-558 expression in cartilage may
contribute to the increased catabolic pathway characteristic of OA
development and identify miR-558 as a promising new target for
OA cartilage protection.
Materials and methods
Materials
Recombinant human IL-1b and antibodies against COX-2 and
MMP-1 were purchased from R&D systems (Minneapolis, MN,
USA). Antibodies against microsomal PGE synthase-1 (mPGES1)
were purchased from Cayman Chemicals (Ann Arbor, Michigan,
USA). Antibodies against phospho-JNK (p-JNK), p-p38, phospho-
inhibitor of kB alpha (p-IkBa) and phospho-extracellular signal-
regulated kinases (p-ERK) were purchased from Cell Signaling
Technology (Beverly, MA, USA). Antibodies against MMP-13 and
b-actin were obtained from Abcam (Cambridge, UK) and Sigma
(St Louis, MO, USA), respectively. Horseradish peroxidase-
conjugated anti-mouse and anti-rabbit secondary antibodies were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
PD98059 [a Mitogen-activated protein kinase kinase (MEK)-1/2
inhibitor], SB203580 [a p38 MAP kinase (MAPK) inhibitor],
SP600125 (a JNK inhibitor) and SN50 [a nuclear factor-kB (NF-kB)
inhibitor] were purchased from Calbiochem (San Diego, CA, USA).
Patients
OA cartilage was obtained from knee joints at the time of total
knee replacement operations from patients [n ¼ 20, mean 
standard deviation (SD) age 71.23  7.10 years] diagnosed accord-
ing to the criteria of the American College of Rheumatology24,25.
Normal cartilage was taken from patients with no previous history
of OA or rheumatoid arthritis (RA) who underwent total hip
replacement surgery due to fracture of the femoral neck (n ¼ 20,
mean SD age 72.12 9.78 years). Normal cartilagewas selected in
area with no surface irregularity while OA cartilage was selected in
areas showing gross erosion. The mean modiﬁed Mankin grades
from OA and normal cartilages were 7.5  1.3 (median 8) and1.9 0.5 (median 1). The collection and use of human samples were
reviewed and approved by the institutional review board of Hallym
University Sacred Heart Hospital (Anyang, Korea).
Cell culture
To isolate primary human chondrocytes, cartilage was dissected
and subjected to sequential digestionwith pronase and collagenase
in serum-free modiﬁed Eagle’s medium (DMEM, Life Technologies,
Inc., MD) until the fragments were digested. First passage-human
chondrocytes at 80% conﬂuence were used for all experiments.
Human chondrogenic SW1353 cells were maintained in Dul-
becco’s modiﬁed Eagle’s medium supplemented with 10% (v/v)
fetal bovine serum (FBS) and 1% penicillin/streptomycin. During the
culture period, cells were incubated at 37C in a humidiﬁed at-
mosphere of 5% CO2 and 95% air and the medium was changed
every 2e3 days.
Transfection of miRNAs
Human chondrocytes were transfected with the mature type of
hsa-miR-558 (Dharmacon, Chicago, IL, USA; 50-UGAGCUGCU-
GUACCAAAAU-30) or the antisense inhibitor (anti-miR-558, Dhar-
macon) at a concentration of 50 nM, using the calcium phosphate
precipitation method. Forty-eight hours after transfection, cells
were stimulated with IL-1b for the indicated time and used for
further analysis. SW1353 cells were seeded in 12- or 24-well plates.
The following day, cells were transfectedwithmiR-558 or anti-miR-
558 at a concentration of 50 nM using Lipofectamine 2000 (Invi-
trogen, CA, USA), according to the manufacturer’s instructions. For
the following experiments, cells were used 48 h after transfection.
Nonspeciﬁc control miR (miR-Control, Dharmacon) was used as a
control for off-target effects.
Quantitative real-time polymerase chain reaction (PCR) analysis of
COX-2 and miR-558 expression
Total cellular RNA was extracted from cultured human chon-
drocytes using TRIzol reagent (Invitrogen, CA, USA). miRNA was
puriﬁed with the mirVana miRNA isolation kit, according to the
manufacturer’s instructions (Ambion, Austin, TX, USA). For some
studies, cartilage from normal and OA donors were milled to a ﬁne
powder in liquid nitrogen and total RNA and miRNAwere prepared
as described above.
Expression levels of COX-2 mRNAwere quantiﬁed using the SYBR
Green PCRMasterMix (Qiagen, Valencia, CA, USA) using a LightCycler
2.0 Instrument (RocheDiagnostics, Indianapolis, IN,USA). GAPDHwas
used as a reference gene. Primer sequences were as follows: COX-2,
forward 50-TGG GAA GCC TTC TCT AAC CTC-30 and reverse 50-TCA
GGAAGCTGCTTTTTACCT T-30; GAPDH, forward 50-TGATGACATCAA
GAA GGT GGT GAA G-30 and reverse 50-TCC TTG GAG GCC ATG TGG
GCCAT-30. Expression ofmaturemiRNAwas quantiﬁed using TaqMan
miRNA assay kit (Applied Biosystems, Foster City, CA, USA). Puriﬁed
miRNA was reverse transcribed using the TaqMan miRNA reverse
transcription kit (Applied Biosystems) andmiRNA-speciﬁc stem-loop
RT primers (Applied Biosystems). Real-time PCRwas performed using
a StepOnePlus Real-time PCR System (Applied Biosystems) in a 10 ml
PCR mixture containing 2 ml RT product, 5 ml TaqMan Universal PCR
Master Mix, 0.2 mM TaqMan probe and 10 mM forward and reverse
primers. RNU6Bwas used as an internal control for miRNA detection.
Immunohistochemical analysis
Formalin-ﬁxed and parafﬁn-embedded cartilage specimens
were sectioned and stained with Safranin O for histological
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parafﬁn sections were dewaxed, rehydrated and treated with 0.05%
trypsin/EDTA solution for 10 min at 37C. Intrinsic peroxidase ac-
tivity was blocked with 3% hydrogen peroxide and sections were
incubated with 1.5% normal goat serum for 30 min and thenwith a
1:150 dilution of polyclonal antibody against COX-2 for 16 h at 4C.
The sections were rinsed and incubated sequentially with bio-
tinylated secondary antibody for 30 min and VECTASTAIN ABC re-
agent (Vector Laboratories, Burlingame, California, USA) for 30 min
at room temperature. All sections were developed with the
ImmPACT 3,30-Diaminobenzidine (DAB) peroxidase substrate kit
(Vector) and counterstained with Mayer’s hematoxylin. Rabbit
immunoglobulin G (IgG) was used as the negative control.
ELISA
The cumulative production of PGE2 and MMP-13 in the culture
supernatants was quantiﬁed using the PGE2 EIA kit (Cayman
Chemical, Ann Arbor, MI, USA) and proMMP-13 immunoassay kit
(R&D Systems), respectively, according to the manufacturer’s
instructions.
Western blot analysis
For protein extraction, culture supernatants were collected and
cells were washed with cold PBS and lysed at 4C in lysis buffer
(50 mM TriseHCl (pH 7.4), 150 mM NaCl, 20 mM EDTA, 1% Triton
X-100, 1% sodium deoxycholate, 0.1% SDS and protease inhibitors).
Proteins were resolved on 10% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) gels and trans-
ferred to polyvinylidene diﬂuoride (PVDF) membranes (Millipore,
Bedford, MA, USA). After blocking with 5% nonfat milk in TBST (Tris-
buffered saline plus 0.1% Tween 20), membranes were incubated
with primary antibodies against COX-2, mPGES1, MMP-1, p-p38,
p-JNK, p-IkBa, p-ERK or b-actin. After washing, primary antibodies
were detected with HRP-conjugated secondary anti-mouse or anti-
rabbit antibodies. The blots were developed using an ECL chem-
iluminescence kit (Santa Cruz).
Luciferase constructs and reporter assay
To create the wild-type COX-2 30 UTR-Luc reporter plasmid
(COX-2 30UTR), a fragment of the 30UTR of the COX-2 gene,
including the predicted miR-558-binding site, was PCR-ampliﬁed
using the following primer sets: forward 50-CTC GAG GAA TCA
AGC CTG GCT ACC TG C ATG CTG TTC C-30 and reverse 50-GCG GCC
GCG GCA CTA GCC TCT TTG CAT C-30, and then cloned into the psi-
CHECK-2 vector downstream of the ﬁreﬂy luciferase gene with
XhoI and NotI. To produce a reporter plasmid with a mutated miR-
558-binding site (COX-2 mut 30UTR), the 30UTR of COX-2 was
ampliﬁed with the following primer set: forward 50-GCA AGT TTT
CAG GTA AAC CTC GAA GCA GGA CTG C-30 and reverse 50-GCA GTC
CTG CTT CGA GGT TTA CCT GAA AAC TTG C-30. The PCR mixture
consisted of 0.7 ml of expanded long range enzyme mix (Roche,
Mannheim, Germany), 10 ml of 5 expanded long range buffer,
100 ng of plasmid template, 100 nM of primers, 3 ml of DMSO and
2.5 ml of dNTPs (10 mM). PCR cycling conditions were as follows:
92C for 30 s, 55C for 1 min, 68C for 10 min and a ﬁnal extension
at 68C for 10 min. After PCR, 20 ml of the reaction was digested
with DpnI at 37C for 1 h and 10 ml was transformed into DH5 alpha
Escherichia coli to prepare the mutant construct plasmids. All con-
structs were conﬁrmed by sequencing (Cosmogenetech, Seoul,
Korea). Cells were co-transfected with wild type- or mutant type-
COX-2 30 UTR-Luc reporter plasmid and miR-Control or miR-558
using Lipofectamine PLUS reagent. Cell lysates were harvested48 h after transfection and luciferase activity was assayed with the
Dual-Glo Luciferase Assay system (Promega, Madison, WI, USA),
according to the manufacturer’s instructions.
To assess modulation of IL-1b-driven NF-kB activation by miR-
558, SW1353 cells were co-transfected with NF-kB luciferase re-
porter plasmid (pNF-kB-Luc, plasmid containing a NF-kB binding
site; Stratagen, Grand Island, NY, USA) and internal control plasmid
pTK-Renilla-luciferase reporter plasmid (Promega), miR-Control or
miR-558 using Lipofectamine PLUS reagent. Forty-eight hours
after transfection, cells were stimulated with IL-1b for 24 h and
luciferase activity was analyzed by the above methods.
Statistical analysis
The data are expressed asmeans 95% conﬁdence intervals (CIs).
Statistical analysis was carried out using KruskaleWallis test for
multiple comparison and P < 0.05 were considered to indicate sta-
tistical signiﬁcance. ManneWhitney U test or Wilcoxon signed-rank
test were used for two group comparisons and Bonferroni P-values
were used to account for multiple testing. All experiments were
performed using samples from at least three different donors with
duplicate or triplicate replication as indicated in the ﬁgure legends.
Results
The expression of miR-558 and COX-2 in normal and OA cartilage
To identify the miRNAs targeting the 30UTR of COX-2 mRNA, we
evaluated numerous miRNAs reported to be regulated by IL-1b in
chondrocytes using miRNA target prediction algorithms, such as
miRanda (http://www.microrna.org), TargetScan (http://www.
targetscan.org) and PicTar (http://pictar.mdc-berlin.de/). We
found that among IL-1b-responsive miRNAs, miR-558 has the po-
tential to regulate COX-2 expression. To assess the potential
involvement of miR-558 in the OA process, we initially attempted to
compare its expression level between normal and OA cartilage. As
shown in Fig. 1A, miR-558 expression was signiﬁcantly reduced in
OA cartilage compared with normal cartilage. Conversely, the high
expression of COX-2 mRNA and protein in OA cartilage compared
with normal cartilage was conﬁrmed by quantitative real-time PCR
and immunohistochemical analysis, respectively [Fig. 1(B) and (C)].
The reverse correlation between IL-1b-regulated COX-2 and miR-
558 expression in normal and OA chondrocytes
Next, we veriﬁed the regulation of miR-558 expression by IL-1b,
a pivotal proinﬂammatory cytokine in OA cartilage. Monolayer
cultured human chondrocytes were treated with IL-1b and the
expressions of miR-558 and COX-2 were determined by quantita-
tive real-time PCR and Western blot analysis, respectively. In
normal chondrocytes, IL-1b stimulation resulted in a signiﬁcant
downregulation of miR-558 at 12 h. MiR-558 expression was
repressed with IL-1b treatment starting at 1 ng/ml [Fig. 2(A)]. In OA
chondrocytes, miR-558 expressionwas signiﬁcantly repressed after
6 h with IL-1b stimulation and the suppression was signiﬁcant at a
1 ng/ml concentration [Fig. 2(B)]. In contrast, COX-2 mRNA
expressionwas increased by IL-1b stimulation in a dose-dependent
manner in both cells [Fig. 2(C) and (D)]. Similarly, COX-2 protein
expressionwas increased with IL-1b stimulation in time- and dose-
dependent manners [Fig. 2(E) and (F)]. Therefore, these results
suggest that abnormally reduced miR-558 expression in OA carti-
lage and in response to IL-1b appear to correlate with increased
COX-2 expression. Faster upregulation of COX-2 mRNA than miR-
558 downregulation in response to IL-1b also indicates that addi-
tional mediators are involved in the regulation of COX-2.
Fig. 1. The expression of mature miR-558 and COX-2 in normal and OA cartilage. (A and B) Relative miR-558 and COX-2 mRNA levels in normal and OA cartilages were determined
by TaqMan miRNA assay and SYBR Green-based real-time PCR, respectively. RNA, U6 small nuclear 2/glyceraldehyde-3-phosphate dehydrogenase (RNU6B/GAPDH) was used as an
endogenous control. Each dot represents a value from single experiment of one donor. Horizontal lines indicate the mean and 95% CIs of the values from seven different donors per
group. (C) COX-2 protein levels were determined by immunohistochemistry using anti-COX-2 polyclonal antibodies. Sections were counterstained with Mayer’s hematoxylin. Data
shown are representative of results from three normal and OA cartilages (magniﬁcation, 400).
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COX-2 expression in human chondrocytes
To investigate which IL-1b signaling pathways regulate the
expression of miR-558 and COX-2, human chondrocytes were pre-
treated for 2 h with NF-kB inhibitor SN50 (5 mM) or various MAPK
inhibitors, such as MEK-1/2 inhibitor PD98059 (10 mM), p38 MAPK
inhibitor SB203580 (1 mM) and JNK inhibitor SP600125 (10 mM), and
then stimulated with IL-1b for 6 or 24 h. In response to IL-1b stim-
ulation, the expression of miR-558 was markedly decreased and
pretreatment with MAPK inhibitors and NF-kB inhibitor attenuated
the inhibitory effects of IL-1b on miR-558 expression [Fig. 3(A)]. In
contrast, IL-1b stimulation resulted in a signiﬁcant increase of COX-2
mRNA and protein expression and treatment with NF-kB and MAPKFig. 2. Regulation of miR-558 and COX-2 expression by IL-1b in human chondrocytes. Nor
various concentrations of IL-1b for the indicated times. (A and B) Expression of miR-558 was
and D) SYBR Green real-time-PCR was used to quantify COX-2 mRNA levels. GAPDH was used
B) and triplicate (C, D) experiment of one donor. Horizontal lines indicate the mean and 95%
for two group comparisons. P-values were computed compared to non-stimulated contr
determined by Western blotting. Western blots are representative of experiments from thrinhibitors suppressed IL-1b-induced COX-2 expression in human
chondrocytes [Fig. 3(B) and (C)]. Consistent with the effect of COX-2
expression, IL-1b-induced PGE2 production was signiﬁcantly
inhibited by NF-kB and MAPK inhibitors [Fig. 3(D)]. These results
suggest that IL-1b-stimulated activation of NF-kB and MAPK
signaling pathways may be necessary for the suppressive effect of
IL-1b on miR-558 expression in human chondrocytes.
Negative regulation of COX-2 and PGE2 production by miR-558 in
human chondrocytes and SW1353 cells
To determine whether miR-558 regulates COX-2 protein
levels, human OA chondrocytes and chondrogenic SW1353 cells
were transfected with mature- or anti-miRNA speciﬁc for miR-mal and OA chondrocytes were deprived of serum for 24 h and then stimulated with
measured by TaqMan assay, and RNU6B was used as an endogenous miRNA control. (C
as an endogenous mRNA control. Each dot represents a mean value from duplicate (A,
CIs of the values from three different donors per group. ManneWhitney U test was used
ols. (E and F) IL-1b-induced COX-2 protein expression in human chondrocytes was
ee different donors with similar results.
Fig. 3. Reverse correlation between miR-558 and COX-2 expression by IL-1b-induced signaling pathways. OA chondrocytes were pretreated for 2 h with the MAPK inhibitors
SB203580 (1 mM), PD98059 (10 mM) or SP600125 (10 mM) and NF-kB inhibitor SN50 (5 mM) and then stimulated with IL-1b for 6 or 24 h. (A) The reduction in miR-558 expression by
IL-1b stimulation was attenuated by pre-treatment with MAPK and NF-kB inhibitors. The expression of miR-558 was determined using TaqMan miRNA assay, and RNU6B was used
as an endogenous control. (B and C) IL-1b-induced COX-2 mRNA and protein expressionwas signiﬁcantly repressed by treatment with MAPK and NF-kB inhibitors. COX-2 mRNA and
protein expression were quantiﬁed by SYBR Green real-time-PCR and Western blotting, respectively. (D) IL-1b-stimulated PGE2 production also decreased after treatment with
MAPK and NF-kB inhibitors. PGE2 levels in culture supernatant were determined by ELISA. Each dot represents a mean value from duplicate (A) and triplicate (B, D) experiment of
one donor. Horizontal lines indicate the mean and 95% CIs of the values from three different donors per group. ManneWhitney U test was used for two group comparisons. P-values
were computed compared to non-stimulated controls* or IL-1b-stimulated controls#. Western blots are representative of experiments from three different donors with similar
results.
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were stimulated with IL-1b for 24 h and COX-2 and PGE2 protein
production was determined by Western blot and ELISA.
Compared to miR-Control-transfected cells, IL-1b-induced COX-2
protein expression in miR-558-transfected cells was signiﬁcantly
suppressed by w30% in both cell types [Fig. 4(A)]. Moreover,
inhibition of endogenous miR-558 by anti-miR-558 led to
elevated IL-1b-stimulated COX-2 protein expression compared to
their controls [Fig. 4(A)]. PGE2 biosynthesis is catalyzed by the
coordinate action of COX enzymes and PGESs. In particular,
mPGES-1, a terminal enzyme one-step downstream of COX-2 is
induced by proinﬂammatory cytokine IL-1b26. Thus, we investi-
gated whether miR-558 affects mPGES1 expression in chon-
drocytes. IL-1b-induced mPGES-1 expression was not
signiﬁcantly different after transfection with miR-558 or anti-
miR-558 [Fig. 4(B)]. Next, we investigated the effect of miR-558
on IL-1b-induced PGE2 production using ELISA. The over-
expression of miR-558 markedly reduced IL-1b-induced PGE2
production by 28% and 35% in human chondrocytes and SW1353
cells, respectively [Fig. 4(C)]. However, transfection with anti-
miR-558 did not alter IL-1b-mediated induction of PGE2 pro-
duction in both cells, possibly due to the expression of mPGES-1
being unaffected by transfection with miR-558 or anti-miR-558
[Fig. 4(B)]. Taken together, these data suggest that COX-2 is a
potential target of miR-558 and is downregulated by miR-558
overexpression in human chondrocytes.MiR-558 targets the 30UTR of COX-2 mRNA
To understand the molecular mechanisms that underlie miR-
558-mediated regulation of COX-2 expression, we analyzed the
sequences in the 30-UTR of human COX-2 mRNA in detail. Bio-
informatic predictions showed that the 30-UTR of human COX-2
mRNA contains a potential miR-558-binding site with 7-mer
seeds and this putative miR-558-binding site and its adjacent
sequences are highly conserved among the vertebrates
[Fig. 5(A)]. To determine if miR-558 inhibits COX-2 gene
expression by binding to the predicted target site in the 30-UTR
of COX-2 mRNA, we generated a wild-type COX-2 30UTR
construct containing a putative miR-558-binding site using psi-
CHECK-2 vector. Co-transfection of COX-2 30UTR luciferase re-
porter plasmids with miR-558 resulted in a signiﬁcant reduction
of luciferase activity [Fig. 5(B)]. In contrast, transfection with
anti-miR-558 enhanced the reporter activity of COX-2 30UTR in
SW1353 cells [Fig. 5(B)]. Next, to further conﬁrm the direct
interaction of miR-558 and COX-2 30UTR, we generated a mutant
reporter plasmid (COX-2 mut 30UTR), in which the binding
sequence in the 30UTR of COX-2 was mutated. As anticipated, a
mutation in the miR-558 binding sequence led to a complete
abrogation of miR-558-mediated repression of COX-2 30UTR re-
porter activity [Fig. 5(C)]. These data demonstrate that miR-558
reduced the luciferase activity by binding to COX-2 30UTR and
COX-2 is a bona ﬁde target of miR-558.
Fig. 4. Inhibitory effects of miR-558 on IL-1b-induced COX-2 and PGE2 production in OA chondrocytes and chondrogenic SW1353 cells. Cells were transfected with miR-Control,
miR-558 or anti-miR-558. Forty-eight hours after transfection, cells were stimulated with IL-1b for 24 h. (A) Compared with miR-control-transfected cells, IL-1b-induced COX-2
expression was signiﬁcantly suppressed by miR-558 overexpression. Conversely, transfection of anti-miR-558 enhanced COX-2 expression in both cell types. COX-2 protein
levels were determined by Western blot analysis and compared with the controls. (B) IL-b1-induced mPGES1 expression was not changed by miR-558 in both cell types. mPGES1
protein levels were determined by Western blot analysis and compared with the controls. (C) Overexpression of miR-558 led to inhibition of IL-1b-stimulated PGE2 production, but
pre-treatment with anti-miR-558 did not alter PGE2 levels compared to their controls in both cell types. PGE2 levels were determined by ELISA. Each dot represents a mean value
from duplicate (B) and triplicate (A, C) experiment of one donor. Horizontal lines indicate the mean and 95% CIs of the values from three different donors per group. ManneWhitney
U test was used for two group comparisons. P-values were computed compared to non-stimulated controls* or IL-1b-stimulated controls#. Western blots are representative of
experiments from six different donors with similar results.
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overexpression in human chondrocytes and SW1353 cells
We found miR-558 to be capable of repressing COX-2, which is
involved in a variety of catabolic responses in OA, so we next eval-
uated the involvement of miR-558 in other IL-1b-induced effects in
chondrocytes. For these studies, human chondrocytes and SW1353
cells were transfected with mature-miR-558 or miR-Control and
then stimulated with IL-1b for the indicated time periods. The
regulatory effects of miR-558 on IL-1b-induced catabolic pathways
were determined by Western blot analysis and luciferase reporter
assay. Overexpression of miR-558 signiﬁcantly inhibited the phos-
phorylation of IkBa in human chondrocytes and SW1353 cells
[Fig. 6(A)]. Likewise, in the luciferase reporter assay, we conﬁrmed
that IL-1b-stimulated NF-kB activity was markedly suppressed by
overexpression of miR-558 in SW1353 cells [Fig. 6(B)]. However
miR-558 overexpression did not affect IL-1b-induced activation of
MAPK including JNK, p38 and ERK in both cells [Fig. 6(A)].
Next, the effects of miR-558 on IL-1b-induced production of
MMPs, which are major proteases responsible for the degradation
of extracellular matrix, mainly collagen, were investigated. Inter-
estingly, miR-558 overexpression signiﬁcantly reduced the
expression of MMP-1 and MMP-13, while transfection with anti-
miR-558 showed increases in the expression of MMP-1 and
MMP-13 in IL-1b-stimulated human chondrocytes and SW1353
cells [Fig. 6(C) and (D)]. Altogether, our results suggest that miR-
558 is an additional crucial regulator of cartilage homeostasis,
which is perturbed by IL-1b in human chondrocytes.Discussion
In this study, we investigated miRNA-mediated post-transcrip-
tional control of COX-2 expression in human chondrocytes. We
demonstrated thatmiR-558, a recently identiﬁedmiRNA regulated by
the potent proinﬂammatory cytokine IL-1b, selectively and directly
regulates COX-2 expression by targeting the 30UTR of COX-2 mRNA.
Overexpression ofmiR-558markedly suppressed IL-1b-induced COX-
2 and PGE2 production, while inhibition of miR-558 function by anti-
miR-558 enhanced IL-1b-induced COX-2 expression.
miRs, as small-molecule regulators of gene expression, are
involved in diverse physiological and pathological processes,
including OA and inﬂammation13,16e18. Identiﬁcation of miRNA
with a functional role in cartilage homeostasis has been attempted
using expression proﬁling and a gene network approach inte-
grating miRNA, proteomic and clinical data16,27,28.
Distinct miRNAs regulating catabolic pathways in chondrocytes
include miR-9, miR-22, miR-27a and b regulating MMP-1318,26,28.
Recently, Akhtar et al. reported that miR-199a* acts as a direct
regulator of COX-2 expression in human OA chondrocytes. They
also showed that reduction of miR-199a expression in OA cartilage
and in response to IL-1b is closely related to enhanced production
of COX-2 in OA cartilages29. The role of a speciﬁc miRNA in in vivo
animal models of arthritis was ﬁrst reported in miR-140 (/)
mice, which showed age-related OA-like changes, in part due to
elevated protease ADAMTS-5 expression20,30.
Currently, there are a number of computational algorithms for
miRNA target prediction which helps to comprehend the speciﬁc
Fig. 5. COX-2 is a target of miR-558. (A) Seed-matched sequences for miR-558 in the 30UTR of COX-2 mRNA and a high level of sequence conservation of their cross species were
identiﬁed by computational algorithms. (B and C) The luciferase reporter assay for the 30UTR of COX-2mRNA in the presence of miR-558. SW1353 cells were co-transfected with wild-
type COX-2 30UTR reporter plasmid or mutated 30-UTR reporter plasmid and miR-Control, miR-558 or anti-miR-558. Forty-eight hours after transfection, luciferase activities were
measured. The ratioof reporter (ﬁreﬂy) to control (renilla)wasplotted. Eachdot represents ameanvalue fromtriplicate experiment of one donor.Horizontal lines indicate themean and
95% CIs of the values from three different donors per group. ManneWhitney U test (B) orWilcoxon signed-rank test (C) was used for two group comparisons. P-values were computed
compared to non-stimulated controls. Bars show the means  95% CI of triplicate experiments from each sample obtained from three different donors. *P < 0.01 vs control.
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Cons conservation score to rank the predictions that consists of a
weighted sum based on matches, mismatches and G:U wobbles,
while TargetScan takes into account a context score based on seed
complementarity, conservation and AU content in the surrounding
mRNA31e35. PicTar algorithm takes into account the overall duplex
stability based on theminimum free energy36,37. Intersecting PicTar
and TargetScan predictions often results in both high sensitivity
and speciﬁcity38e40.
MiR-558 is upregulated inmesenchymal cells derived from aged
rhesus macaque bone marrow and in ﬁbroblasts irradiated with
high doses of radiation23,41. TargetScan contains more than 270
predicted targets of miR-558, some of which are relevant to the
maintenance of cartilage homeostasis (e.g., serine/threonine kinase
4 (STK4) and PDZ domain containing 4 (PDZD4)). While the role of
miR-558 requires further research, it is of note that miR-558
exhibited oncogenic effects by increasing proliferation and colony
formation in neuroblastoma cell lines42.
Our results suggest that in human OA cartilage, the level of miR-
558 expression is appreciably reduced compared to that in normal
cartilage. We found that IL-1b-mediated MAPK and NF-kB signal
pathways are involved in an inverse correlation of expression of
miR-558 and COX-2 in human chondrocytes. We identiﬁed the pu-
tative binding sequence of miR-558 in the 30UTR of COX-2 mRNA
locatedw1,400bpdownstreamof the stop codon of the COX-2 gene,
demonstrating that miR-558 is a bona ﬁde regulator of COX-2 in
chondrocytes. Although selective COX-2 inhibitors may hamper
catabolic cytokine-induced cartilage degeneration, considering theside effect proﬁles of these agents, understanding of its speciﬁc and
detailed regulatory mechanism is required.
In IL-1b-stimulated human chondrocytes, treatment with anti-
miR-558 enhanced COX-2 expression, but did not affect PGE2 pro-
duction. The expression of mPGES-1 was not regulated by trans-
fection of miR-558 and anti-miR-558. It has been known that
mPGES-1 is a major down-step enzyme of COX-2 in PGE2 biosyn-
thesis and regulates IL-1b-induced PGE2 upregulation9,43. Inter-
estingly, we observed that overexpression of miR-558 inhibited IL-
1b-mediated activation of the catabolic pathway rather broadly,
including NF-kB and production of MMP-1 and MMP-13 in human
chondrocytes and SW1353 cells. These results suggest that miRNA
may amplify its own effect by targeting a set of genes in a common
pathway or protein complex. On the other hand, activation of NF-kB
by IL-1b signiﬁcantly inhibited miR-558 expression, suggesting a
reciprocal regulatory loop. Similar negative regulation of miRNAs in
chondrocytes by activated MAPKs and NF-kB was also reported
previously21,29. These results suggest that miRNA may constitute a
regulatory motif that acts as both a transcription factor and a
mutual negative feedback network, highlighting the importance of
elucidating the pathways regulated by miRNA.
The present study has some limitations: First, owing to the difﬁ-
culty in obtaining normal knee andOAhip cartilages from the elderly
in Korea, differences in expression of miR-558 and COX-2 according
to joint sites could not be ascertained. Although there may be joint
speciﬁc distinctions, recent study showed that osteoarthritic gene
expressionpatterns in cells derived fromhiporknee joint ex vivo and
inprimaryculturewerenot signiﬁcantly different44. Second,weused
Fig. 6. MiR-558 suppresses IL-1b-mediated catabolic responses in OA chondrocytes and SW1353 cells. (A) To evaluate the regulation of IL-1b-driven signaling pathways by miR-558,
cells were transfected with miR-Control or miR-558. After transfection, cells were stimulated with IL-1b for the indicated times and p-JNK, p-p38, p-IkBa and p-ERK levels in total
cell lysates were determined by Western blot analysis. Protein levels were normalized to that of b-actin. (B) The inhibitory effect of miR-558 on IL-1b-induced NF-kB activation was
further conﬁrmed by luciferase reporter assay using a NF-kB luciferase reporter plasmid. Overexpression of miR-558 markedly suppressed the reporter activity of NF-kB in SW1353
cells. (C and D) Forty-eight hours after transfection, cells were incubated with IL-1b for 24 h and the levels of MMP-1 and MMP-13 protein in culture supernatant were evaluated by
Western blot and ELISA, respectively. Each dot represents a mean value from triplicate experiment of one donor. Horizontal lines indicate the mean and 95% CIs of the values from
three different donors per group. ManneWhitney U test was used for two group comparisons. P-values were computed compared to non-stimulated controls* or IL-1b-stimulated
controls#. Western blots are representative of experiments from three different donors with similar results.
S.J. Park et al. / Osteoarthritis and Cartilage 21 (2013) 981e989988chondrocytes of passage 1 culture. By minimizing the duration of
monolayer culture using high density plating, we could minimize
dedifferentiation, althoughaslight degreeofde-differentiationcould
not be avoided which might have inﬂuenced our data. Finally, the
regulation conferred by miRNA is usually redundant, meaning that
IL-1b regulates numerous miRNAs in addition to miR-558, while
COX-2 is regulatedbymiRNAsother thanmiR-558.Thusconﬁnement
of theregulatory loopof IL-1 inducedCOX-2tomiR-558would lead to
a reductionist point of view.
In conclusion, we found that miR-558 functions as a negative
regulator of IL-1b-mediated catabolic responses by repressing COX-
2 expression and catabolic signaling pathways in human chon-
drocytes. To explore potential application of miR-558 as a thera-
peutic agent, further study is needed to evaluate the effectiveness
and safety of miR-558 in vivo, and technological advance to
enhance its efﬁcacy of delivery using viral vector or nanoparticle-
based system are needed.
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